Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck/Biomira Lung Cancer Vaccine Phase III To Start Mid-2006 Following Deal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck KGaA and Biomira will begin Phase III studies of lung cancer vaccine BLP25 in mid-2006, according to Biomira

You may also be interested in...

Licensing In Brief

Gene Logic to revive Pfizer drug candidates: Several Pfizer drug candidates not currently in active development could be revived through a partnership with Gene Logic, announced Sept. 27. Gene Logic's Drug Repositioning and Selection Program uses a range of technologies to evaluate a drug's potential utility, and could "restore stalled drug candidates back into [Pfizer's] clinical development pipeline," Gene Logic says. In addition to the "significant number" of candidates from Pfizer, Gene Logic currently is reviewing one stalled Phase II candidate from Millennium and 16 Phase II and III candidates from an undisclosed company. Another firm with plans to develop a pipeline based on in-licensing stalled drug candidates is Genaissance; the firm licensed the antidepressant vilazodone from Merck KgaA in September 2004 (1Pharmaceutical Approvals Monthly October 2004, p. 27)...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts